Marrone Bio Innovations Inc.Find Ratings Reports
MARRONE BIO INNOVTIONS's gross profit margin for the second quarter of its fiscal year 2019 has increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. MARRONE BIO INNOVTIONS has weak liquidity. Currently, the Quick Ratio is 0.97 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 84.08% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY19||Q2 FY18|
|Net Sales ($mil)||7.0||5.75|
|Net Income ($mil)||-6.75||-4.87|
|Balance Sheet||Q2 FY19||Q2 FY18|
|Cash & Equiv. ($mil)||9.47||23.3|
|Total Assets ($mil)||47.35||55.14|
|Total Debt ($mil)||28.68||21.84|
|Profitability||Q2 FY19||Q2 FY18|
|Gross Profit Margin||60.84||56.1|
|Return on Assets||-43.83||-47.22|
|Return on Equity||-593.67||-118.55|
|Debt||Q2 FY19||Q2 FY18|
|Share Data||Q2 FY19||Q2 FY18|
|Shares outstanding (mil)||110.73||110.47|
|Div / share||0.0||0.0|
|Book value / share||0.03||0.2|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||134462.0||129387.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 41.27 indicates a significant premium versus the S&P 500 average of 3.24 and a significant premium versus the subsector average of 3.91. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. Upon assessment of these and other key valuation criteria, MARRONE BIO INNOVTIONS seems to be trading at a premium to investment alternatives.
|MBII NM||Peers 37.25||MBII NM||Peers 17.83|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
MBII's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
MBII's P/CF is negative making the measure meaningless.
|MBII NM||Peers 20.47||MBII NA||Peers 1.33|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
MBII's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|MBII 41.27||Peers 3.91||MBII 69.36||Peers 42.90|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
MBII is trading at a significant premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
MBII is expected to have an earnings growth rate that significantly exceeds its peers.
|MBII 5.36||Peers 2.51||MBII 52.48||Peers 21.48|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
MBII is trading at a significant premium to its subsector.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
MBII has a sales growth rate that significantly exceeds its peers.